ID
27403
Description
Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977
Keywords
Versions (2)
- 11/13/17 11/13/17 -
- 11/26/17 11/26/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
November 13, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Contact #2 Year 2 GSK study Prostatic neoplasms NCT00883909
Contact #2 Year 2 GSK study Prostatic neoplasms NCT00883909
- StudyEvent: ODM
Description
Subject contact
Description
If YES, record the date and type of contact.
Data type
text
Description
Date of contact
Data type
date
Description
Type of contact
Data type
text
Description
If YES, ensure that all questions in the CONTACT #2 section have been completed. If NO, check primary reason interview was not completed and do not complete the questions in the CONTACT #2 section.
Data type
text
Description
If subject died, record details on the SERIOUS ADVERSE EVENT pages.
Data type
text
Description
Other primary reason interview was not completed
Data type
text
Description
CONTACT #2 - Since Contact #1 (if contact #1 was performed) OR Since the REDUCE 4 Year Contact (if contact #1 was not performed):
Description
If YES, Record the date of collection and local PSA results on the PSA RESULTS page.
Data type
text
Description
If YES, • Enter the biopsy information and the local pathology results on the LOCAL PATHOLOGY RESULTS page. • Send biopsy sample to Central Pathology for Confirmatory Review only if the result is positive for prostate cancer. • If biopsy is positive for PCa enter any available new TNM stage information on the TNM STAGING HISTORY page.
Data type
text
Description
If YES, • Enter surgical treatment for PCa on the PROSTATIC SURGICAL INTERVENTION page; and, • For radical prostatectomy, enter any local pathology information/ result on LOCAL PATHOLOGY RESULTS page. • For radical prostatectomies, send surgical sample to Central Pathology for confirmatory review, regardless of whether the result is positive or negative for prostate cancer. • For all prostate surgeries other than radical prostatectomies, send surgical sample to Central Pathology for confirmatory review only if the result is positive for prostate cancer. • Enter non-surgical treatment for PCa, on the NON-SURGICAL INTERVENTION FOR PROSTATE CANCER page. • Complete any further TNM staging information on the TNM STAGING HISTORY page.
Data type
text
Description
If YES, • Enter the prostate surgery information on the PROSTATE SURGICAL INTERVENTION page; and, • Enter local pathology results for the surgery on the LOCAL PATHOLOGY RESULTS page. • Send surgical sample to Central Pathology for confirmatory review only if the result is positive for prostate cancer. • Complete any further TNM staging information on the TNM Staging History page.
Data type
text
Description
medical problems or hospitalisations
Data type
text
Description
If YES, Complete the SERIOUS ADVERSE EVENT pages and ensure they are faxed to GSK within 24 hours of becoming aware of the event.
Data type
text
Description
Chronic concomitant medications include all prescription and nonprescription medication including vitamins, supplements and herbal remedies. Specifically include the use of dutasteride [Avodart ®] or finasteride [Proscar ® and Propecia ®]. If YES, • Enter information for all changes in chronic medications on the CONCOMITANT MEDICATIONS page(s).
Data type
text
Similar models
Contact #2 Year 2 GSK study Prostatic neoplasms NCT00883909
- StudyEvent: ODM